Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma plc executive George W. Lloyd, EVP, Investments & CLO, reported multiple sales of Class A Ordinary Shares of RPRX on 11/19/2025. The transactions, coded as open-market sales, were executed under a Rule 10b5-1 trading plan adopted on August 20, 2025, meaning they followed a pre-set schedule. Shares were sold indirectly through several family-related entities, with weighted average prices generally between about $37.77 and $39.34 per share, and smaller sales from directly held shares.
After the reported sales, Lloyd continues to hold Class A Ordinary Shares through multiple vehicles, as well as limited partnership interests in RPI US Partners 2019, LP that are exchangeable into 7,527,320 Class A Ordinary Shares. He also holds 1,944,471 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, some of which may convert into an equivalent number of Class A Ordinary Shares upon vesting.
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported open-market sales of Class A Ordinary Shares of Royalty Pharma plc (RPRX) on 11/17/2025. The transactions, made under a Rule 10b5-1 trading plan adopted on August 8, 2025, included the sale of 65,844 Class A Ordinary Shares by TPC RP 2021, LLC at a weighted average price of $39.3041 per share and 3,750 Class A Ordinary Shares by TPC RP EPA1 LLC at a weighted average price of $39.304 per share.
Following these trades, the filing reports 724,156 Class A Ordinary Shares held indirectly through TPC RP 2021, LLC and 54,760 Class A Ordinary Shares held indirectly through TPC RP EPA1 LLC, along with additional indirect and direct holdings through IRAs, a spouse’s IRA, and personal accounts. The filing also notes limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares and ownership of 1,807,277 Class E Ordinary Shares of Royalty Pharma Holdings Ltd that may convert into an equivalent number of Class A Ordinary Shares upon vesting.
Royalty Pharma (RPRX) CEO and Chairman Pablo G. Legorreta reported an exempt acquisition of Class A Ordinary Shares. On 11/05/2025, he acquired 36,559 shares at $0 (code A) pursuant to Rule 16b-3 in connection with the settlement of Equity Performance Awards.
Following the transaction, his direct beneficial ownership stands at 940,955 shares. He also reports indirect holdings through various entities, including 1,040,410 shares by the Legorreta Children 2002 Trust and 901,590 shares by the GST-Exempt Legorreta 2012 Family Trust.
Royalty Pharma (RPRX) EVP & CFO reported an exempt acquisition of 6,168 Class A Ordinary Shares on 11/05/2025 at $0 per share under Rule 16b-3, tied to the settlement of Equity Performance Awards.
Following this transaction, 58,510 shares were beneficially owned through TPC RP EPA1 LLC. The filing also lists additional holdings in various accounts, including 1,500 shares held directly and 790,000 shares held indirectly by TPC RP 2021, LLC.
Royalty Pharma plc (RPRX) reported an insider transaction on a Form 4. The EVP, Investments & CLO acquired 6,168 Class A Ordinary Shares on 11/05/2025 at $0, an exempt acquisition under Rule 16b-3 tied to the settlement of Equity Performance Awards.
Following the transaction, the reporting person lists beneficial ownership across multiple indirect entities, including GWL 2023 G HoldCo LLC, GWL 2013 NG, LLC, an IRA, GWL 2014 G, LLC, GWL 2020 G, LLC, GWL 2021 G, LLC, and by spouse, as well as 3,000 shares held directly.
Royalty Pharma (RPRX) executive Christopher Hite reported an exempt acquisition of 6,168 Class A Ordinary Shares at $0 on 11/05/2025, in connection with the settlement of Equity Performance Awards pursuant to Rule 16b-3.
Following the reported transaction, Hite beneficially owns 658,510 shares indirectly through SCH Investment Partners LLC and 70,000 shares directly.
Royalty Pharma (RPRX) Form 4: EVP, Research & Investments Marshall Urist reported two equity acquisitions. On 11/05/2025, he acquired 4,626 Class A Ordinary Shares at $0 in connection with the settlement of Equity Performance Awards. On 11/07/2025, he converted limited partnership interests in RPI US Partners 2019, LP into 160,000 Class A Ordinary Shares at $0 pursuant to an exchange agreement; these shares are held indirectly via Sandy Lamm LLC.
After these transactions, beneficial ownership includes 43,882 shares held directly, 206,667 shares held indirectly via Sandy Lamm LLC, and 19,020 shares held indirectly via an IRA. He also reports 247,412 LP interests remaining, which are exchangeable into Class A shares under the stated terms.
Royalty Pharma (RPRX) filed its Q3 2025 10-Q, showing higher top-line but lower profitability as internalization-related expenses flowed through. Total income and other revenues were $609.3 million, up from $564.7 million a year ago, driven by $578.8 million of income from financial royalty assets. Operating income was $427.2 million versus $735.1 million, reflecting a tougher comparison to last year’s favorable provision swing and much higher share-based compensation tied to the May internalization.
Net income attributable to Royalty Pharma plc was $288.2 million ($0.67 diluted EPS) versus $544.0 million ($1.21 diluted EPS) in Q3 2024. Year to date, net cash from operating activities totaled $1.66 billion, while investing included $964.0 million of acquisitions of financial royalty assets and $268.6 million of milestone payments. The company repurchased $1.15 billion of Class A shares year to date and paid $0.66 per share in dividends. The balance sheet added $924.6 million of goodwill and $502.9 million of accrued compensation liabilities from the internalization; long‑term debt was $8.57 billion. As of October 31, 2025, Class A shares outstanding were 427,247,489 and Class B were 149,990,618.
Royalty Pharma plc furnished an Item 2.02 Form 8-K announcing its financial results press release for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and the Cover Page Inline XBRL is listed as Exhibit 104.
The information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference except as expressly stated.
Bonnie L. Bassler, a director of Royalty Pharma plc (RPRX), reported a change in beneficial ownership on 09/30/2025. The Form 4 shows an acquisition of 1,047 Class A ordinary shares at a reported price of $35.7872 per share, described as shares issued under the company's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. The filing lists 72,165 shares as the amount of securities beneficially owned following the reported transaction. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Bassler.